Fingerprint
Dive into the research topics of 'Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: Results from the phase III, randomized ATLAS trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: Results from the phase III, randomized ATLAS trial
M. Gross-Goupil, T. G. Kwon, M. Eto, D. Ye, H. Miyake, S. I. Seo, S. S. Byun, J. L. Lee, V. Master, J. Jin, R. DeBenedetto, R. Linke, M. Casey, B. Rosbrook, M. Lechuga, O. Valota, E. Grande, D. I. Quinn
- Centre Hospitalier Universitaire de Bordeaux
- Kyushu University
- Fudan University
- Tokoha University
- Sungkyunkwan University
- Seoul National University
- University of Ulsan
- Emory University
- Peking University
- SFJ Pharmaceuticals
- Pfizer
- Pfizer Oncology
- University of Texas MD Anderson Cancer Center
- University of Southern California
Research output: Contribution to journal › Article › peer-review
209
Scopus
citations